A long-term study of the hematological and metabolic effects of a low-dose monophasic oral contraceptive containing gestodene

S. B. Solerte, M. Fioravanti, A. Spinillo, P. Berard, S. Severgnini, E. Ferrari, S. Guaschino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This long-term metabolic and hemorheological study investigated the effects of monophasic contraceptive treatment with 30 μg ethinylestradiol/75 μg gestodene in 20 healthy young women. No modifications of arterial blood pressure levels, blood/plasma serum viscosity and erythrocyte deformability were demonstrated during the study. Likewise, α2-macroglobulin serum concentrations and hemostatic parameters (fibrinogen, fibronectin, antithrom-biti III, Von Willebrand factor antigen) remained unchanged in the 2-year follow-up period. Concerning the metabolic action of oral contraception on lipid, lipoprotein and apolipoprotein patterns, no significant variations of high-density lipoprotein (HDL)-, low-density lipoprotein (LDL)-, very low density lipoprotein (VLDL)-cholesterol, triglyceride, non-esterified fatty acids (NEFA), LDL-, HDL-, VLDL-lipoprotein and apolipoprotein A-I, A and B levels werefound throughout the 24 months of treatment with the monophasic pill. No differences for each parameter studied were observed at the end of the study between women treated with oral contraceptives and a matched group of healthy controls. The gestodene/ethinylestradiol monophasic combination may therefore represent an important therapeutic approach in order to avoid metabolic and cardiovascular complications during long-term hormonal contraception.

Original languageEnglish
Pages (from-to)5-12
Number of pages8
JournalGynecological Endocrinology
Volume10
Issue numberSUPPL. 5
DOIs
Publication statusPublished - 1996

Fingerprint

Oral Contraceptives
Ethinyl Estradiol
HDL Lipoproteins
Contraception
LDL Lipoproteins
Erythrocyte Deformability
VLDL Cholesterol
Macroglobulins
VLDL Lipoproteins
Apolipoproteins
Apolipoprotein A-I
von Willebrand Factor
Apolipoproteins B
Hemostatics
Contraceptive Agents
Serum
Fibronectins
Viscosity
Fibrinogen
Lipoproteins

Keywords

  • Gestodene
  • Hemorheology
  • Oral Contraceptive

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Obstetrics and Gynaecology

Cite this

A long-term study of the hematological and metabolic effects of a low-dose monophasic oral contraceptive containing gestodene. / Solerte, S. B.; Fioravanti, M.; Spinillo, A.; Berard, P.; Severgnini, S.; Ferrari, E.; Guaschino, S.

In: Gynecological Endocrinology, Vol. 10, No. SUPPL. 5, 1996, p. 5-12.

Research output: Contribution to journalArticle

Solerte, S. B. ; Fioravanti, M. ; Spinillo, A. ; Berard, P. ; Severgnini, S. ; Ferrari, E. ; Guaschino, S. / A long-term study of the hematological and metabolic effects of a low-dose monophasic oral contraceptive containing gestodene. In: Gynecological Endocrinology. 1996 ; Vol. 10, No. SUPPL. 5. pp. 5-12.
@article{04648bf1aa2244908515c7f6680ea1f1,
title = "A long-term study of the hematological and metabolic effects of a low-dose monophasic oral contraceptive containing gestodene",
abstract = "This long-term metabolic and hemorheological study investigated the effects of monophasic contraceptive treatment with 30 μg ethinylestradiol/75 μg gestodene in 20 healthy young women. No modifications of arterial blood pressure levels, blood/plasma serum viscosity and erythrocyte deformability were demonstrated during the study. Likewise, α2-macroglobulin serum concentrations and hemostatic parameters (fibrinogen, fibronectin, antithrom-biti III, Von Willebrand factor antigen) remained unchanged in the 2-year follow-up period. Concerning the metabolic action of oral contraception on lipid, lipoprotein and apolipoprotein patterns, no significant variations of high-density lipoprotein (HDL)-, low-density lipoprotein (LDL)-, very low density lipoprotein (VLDL)-cholesterol, triglyceride, non-esterified fatty acids (NEFA), LDL-, HDL-, VLDL-lipoprotein and apolipoprotein A-I, A and B levels werefound throughout the 24 months of treatment with the monophasic pill. No differences for each parameter studied were observed at the end of the study between women treated with oral contraceptives and a matched group of healthy controls. The gestodene/ethinylestradiol monophasic combination may therefore represent an important therapeutic approach in order to avoid metabolic and cardiovascular complications during long-term hormonal contraception.",
keywords = "Gestodene, Hemorheology, Oral Contraceptive",
author = "Solerte, {S. B.} and M. Fioravanti and A. Spinillo and P. Berard and S. Severgnini and E. Ferrari and S. Guaschino",
year = "1996",
doi = "10.3109/09513599609049603",
language = "English",
volume = "10",
pages = "5--12",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "SUPPL. 5",

}

TY - JOUR

T1 - A long-term study of the hematological and metabolic effects of a low-dose monophasic oral contraceptive containing gestodene

AU - Solerte, S. B.

AU - Fioravanti, M.

AU - Spinillo, A.

AU - Berard, P.

AU - Severgnini, S.

AU - Ferrari, E.

AU - Guaschino, S.

PY - 1996

Y1 - 1996

N2 - This long-term metabolic and hemorheological study investigated the effects of monophasic contraceptive treatment with 30 μg ethinylestradiol/75 μg gestodene in 20 healthy young women. No modifications of arterial blood pressure levels, blood/plasma serum viscosity and erythrocyte deformability were demonstrated during the study. Likewise, α2-macroglobulin serum concentrations and hemostatic parameters (fibrinogen, fibronectin, antithrom-biti III, Von Willebrand factor antigen) remained unchanged in the 2-year follow-up period. Concerning the metabolic action of oral contraception on lipid, lipoprotein and apolipoprotein patterns, no significant variations of high-density lipoprotein (HDL)-, low-density lipoprotein (LDL)-, very low density lipoprotein (VLDL)-cholesterol, triglyceride, non-esterified fatty acids (NEFA), LDL-, HDL-, VLDL-lipoprotein and apolipoprotein A-I, A and B levels werefound throughout the 24 months of treatment with the monophasic pill. No differences for each parameter studied were observed at the end of the study between women treated with oral contraceptives and a matched group of healthy controls. The gestodene/ethinylestradiol monophasic combination may therefore represent an important therapeutic approach in order to avoid metabolic and cardiovascular complications during long-term hormonal contraception.

AB - This long-term metabolic and hemorheological study investigated the effects of monophasic contraceptive treatment with 30 μg ethinylestradiol/75 μg gestodene in 20 healthy young women. No modifications of arterial blood pressure levels, blood/plasma serum viscosity and erythrocyte deformability were demonstrated during the study. Likewise, α2-macroglobulin serum concentrations and hemostatic parameters (fibrinogen, fibronectin, antithrom-biti III, Von Willebrand factor antigen) remained unchanged in the 2-year follow-up period. Concerning the metabolic action of oral contraception on lipid, lipoprotein and apolipoprotein patterns, no significant variations of high-density lipoprotein (HDL)-, low-density lipoprotein (LDL)-, very low density lipoprotein (VLDL)-cholesterol, triglyceride, non-esterified fatty acids (NEFA), LDL-, HDL-, VLDL-lipoprotein and apolipoprotein A-I, A and B levels werefound throughout the 24 months of treatment with the monophasic pill. No differences for each parameter studied were observed at the end of the study between women treated with oral contraceptives and a matched group of healthy controls. The gestodene/ethinylestradiol monophasic combination may therefore represent an important therapeutic approach in order to avoid metabolic and cardiovascular complications during long-term hormonal contraception.

KW - Gestodene

KW - Hemorheology

KW - Oral Contraceptive

UR - http://www.scopus.com/inward/record.url?scp=80051927608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051927608&partnerID=8YFLogxK

U2 - 10.3109/09513599609049603

DO - 10.3109/09513599609049603

M3 - Article

VL - 10

SP - 5

EP - 12

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - SUPPL. 5

ER -